Results of a small Phase 1 study indicate that the investigational drug mila­tu­zu­mab on its own has limited efficacy in patients with advanced relapsed and re­fractory multiple myeloma.

The best response the investigators observed in their study was stable disease, which 20 percent of the patients achieved. One patient con­tin­ued to have stable disease without progression for 17 months.

According to the investigators, these results are in line with those for sev­er­al other agents in the same class of drugs, such as siltuximab and elo­tuzumab, which have shown modest …

Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, it is currently being investigated as a treatment of multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.

Clinical Trials:
For a list of clinical trials studying milatuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official website for milatuzumab: http://www.immunomedics.com/5clinical/Milatuzumab.html